Assessment of Effect of Adintrevimab on COVID-19 Vaccine Response

Kazima Tosh¹, Deepali Gupta¹, Anna Holmes¹, Yong Li¹, Pamela Hawn¹, Pete Schmidt¹, Kristin Narayan¹ ¹Invivyd, Inc., Waltham, MA, USA

INTRODUCTION

- Monoclonal antibodies (mAbs) have been studied and administered as pre-exposure prophylaxis for COVID-19
- Many of the patients who were administered mAbs for prevention of COVID-19 would likely also have received primary series vaccination(s) as well as boosters
- Bamlanivamab, a mAb used for COVID-19, has previously been shown to not impact antibody response to vaccination¹
- Impact of receptor binding domain (RBD)-directed COVID-19 mAbs on immune response to COVID-19 vaccines is critical to understand as both are key parts of a preventive strategy
- Adintrevimab has shown potent activity through the Delta variant but reduced in vitro neutralization against Omicron BA.1/BA1.1 sublineages and no neutralizing activity against other Omicron sublineages
- Adintrevimab was studied in both a Phase 1 first in human study and a Phase 2/3 study in the prevention of COVID-19 (EVADE, NCT04859517)
- As part of these studies, the effect of adintrevimab on the vaccine response was assessed; here, we report those findings

METHODS

Study design and participants

- Participants receiving 300 mg intramuscular (IM) dose of adintrevimab were pooled across phase 1 and phase 2/3 prevention studies
 - Phase 1: Randomized, double-blind, single ascending-dose study evaluating the safety and tolerability, pharmacokinetics, and immunogenicity of ascending intravenous (IV) or IM doses of adintrevimab
 - EVADE: Multicenter, double-blind, placebo-controlled phase 2/3 trial for prevention of COVID-19
- Participants had to be seronegative prior to start of both studies but were allowed to receive a COVID-19 vaccine during the follow-up period
- Assessments were performed prior to vaccination and 2 weeks after final vaccine dose, including the collection of blood samples to measure serum virus neutralizing antibody (sVNA) titers
- sVNA titers were determined against SARS-CoV-2 D614G (BavPat1/2020) using a validated microneutralization method at Viroclinics, B.V. (Rotterdam, The Netherlands)
- These were reported using a measure of maximum serum dilution that reduced the plaque number by 80% (MN80) using methodology by Zielinska et al.²
- Additionally, vaccine-derived sVNA titers were measured by blocking adintrevimab activity in serum using a specific anti-idiotype (anti-ID) reagent prior to microneutralization
 - A maximum adintrevimab serum concentration of 100 µg/mL (observed across doses in the phase 1 and EVADE studies) was assumed for all samples
 - To block adintrevimab, a 10-fold excess of anti-ID blocking antibody was spiked into starting dilutions of serum, from participants that received adintrevimab or placebo.
 - Control testing demonstrated the 10-fold excess of anti-ID completely blocked the SARS-CoV-2 neutralizing activity of adintrevimab without nonspecific inhibition of other neutralizing antibodies
- Descriptive statistics are used to describe demographics, total sVNA titers and vaccine-derived sVNA titers

REFERENCES

- 1. Benschop RJ, et al. Science Translational Medicine. 2022;14(655).
- 2. Zielinska E, et al. Virology Journal. 2005;2:84.
- 3. ADG20-DOF-011. Invivyd, Inc. 2023.
- 4. ADG20-DOF-012. Invivyd, Inc. 2023.
- 5. ADG20-DOF-013. Invivyd, Inc. 2023.

DISCLOSURES

Adintrevimab is a fully human immunoglobulin (Ig) G1 mAb derived from a survivor of the SARS 2003 epidemic that targets the RBD

- KT, DG, AH, YL, PH, PS, and KN are all employees of Invivyd and may own stock
- Adintrevimab is an investigational product candidate that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.

RESULTS

Baseline Characteristics³

- A total of 52 participants were included in the analysis (n=21 adintrevimab, n=31 placebo)
- Baseline characteristics were balanced between groups (Table 1)
- Participants received 1-2 doses of COVID-19 vaccine, including Pfizer, Moderna, or J&J
- Median time to first vaccination following study dosing was 24.5 weeks (min, max: 9, 36) for the adintrevimab treated group and 10 weeks (min, max: 4, 37) for the placebo group

Table 1. Baseline characteristics		
Characteristic	Adintrevimab n=21	Placebo n=31
Median age (range), years	40 (28–64)	41 (18–62)
Female, n (%)	12 (57.1)	15 (48.4)
Race, n (%) White Black or African American Native Hawaiian or Other Pacific Islander Other American Indian or Alaskan Native Multiple	15 (71.4) 5 (23.8) 1 (4.8) 0 0 0	24 (77.4) 2 (6.5) 0 2 (6.5) 1 (3.2) 2 (6.5)
BMI, mean (SD), kg/m ²	30.85 (10.1)	29.68 (7.99)

Neutralizing antibody titers^{4,5}

- with no impact on vaccine response by adintrevimab (**Figure 1**)
- to vaccination in adintrevimab and placebo groups (Figure 2)




Figure 1. Pre- and Post-Vaccination sVNA Titers*

actual data.

• Prior to vaccination, geometric mean MN80 titers were higher in the adintrevimab group (75.9) compared to the placebo group (11.1) • Post-vaccination geometric mean MN80 titers were comparable across groups, adintrevimab group (201.3) vs placebo group (101.6), consistent

Pre-treatment of serum with a specific anti-ID reagent to block adintrevimab activity demonstrated comparable neutralizing antibody responses due



*Box and triangle denote median, interquartile range (IQR), and geometric mean, respectively. Whisker end points are equal to the maximum and minimum values below or above the median ±1.5 times the IQR. Closed circle points indicate

KEY FINDINGS



Adintrevimab, a monoclonal antibody targeting the RBD on SARS-CoV-2, did not impact neutralizing antibody response to **COVID-19** primary vaccination



Targeted blocking of adintrevimab with anti-idiotype reagent in vitro demonstrated comparable neutralizing antibody response to vaccination in both adintrevimab and placebo groups

CONCLUSIONS

- Adintrevimab and bamlanivamab have both demonstrated minimal impact on neutralizing antibody response to vaccination
- Taken together, RBD-directed COVID-19 mAbs do not appear to inhibit the development of neutralizing antibodies after vaccination
- These data support the use of mAbs as part of a COVID-19 prevention plan in patients who may have impaired responses to vaccination and/or require additional protection

Invivyd Inc. Waltham, MA, USA